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Abstract
The presence of thrombi in the atherosclerotic and/or aneurysmatic aorta with peripheral arterial
embolism is a common scenario. Thrombus formation in a morphologically normal aorta, however,
is a rare event. A 50 years old woman was admitted to the mergency department for pain, coldness,
and anesthesia in the the left foot. She had a 25 years history of cigarette smoking, a history of
postmenopausal hormone replacement therapy (HRT), hypercholesterolemia and
hyperfibrinogenemia. An extensive serologic survey for hypercoagulability, including
antiphospholipid antibodies, and vasculitis disorders was negative. Transesophageal
echocardiography revealed a large, pedunculated and hypermobile thrombus attached to the aortic
wall 5 cm distal of the left subclavian artery. The patient was admitted to the surgery department,
where a 15 cm long fresh, parietal thrombus could be removed from the aorta showing no
macroscopic wall lesions or any other morphologic abnormalities.
This case report demonstrates the possibility of evolving a large, pedunculated thrombus in a
morphologically intact aorta in a postmenopausal woman with thrombogenic conditions such as
hyperfibrinogenemia, hypercholesterolemia, smoking and HRT. For these patients, profiling the
individual risk and weighing the benefits against the potential risks is warranted before prescribing
HRT.
Background
The cardiac cavities are in >85 % of cases the primary
source of peripheral arterial embolism (PAE). Due to new
and sophisticated imaging techniques in recent years,
such as spiral computed tomography (CT) scan, magnetic
resonance imaging (MRI) and transesophageal echogra-
phy (TEE), noncardiac sources of PAE has been detected
with increasing frequency. Among these non-cardiac
sources, the aorta has been reported in up to 5 % of cases
to be the origin of PAE [1]. However, while mural throm-
bus in the aneurysmatic or atherosclerotic aorta with pro-
truding atheromas may be the source of major arterial
embolism [2], emboli originating from a non-atheroma-
tous and non-aneurysmatic aorta is a rare event [3]. We
report a case of pedunculated, large and highly mobile
thrombus, formed within a morphologically normal
descending thoracic aorta, resulting in recurrent periph-
eral embolism that caused acute ischemia of the lower
extremities.
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Case report, diagnostic workup and therapeutic 
intervention
A 50 years old woman was admitted to the emergency
department because of acute pain, coldness, and anesthe-
sia in the left foot. Pulses at the left popliteal, tibialis pos-
terior and at the dorsalis pedis artery were not palpable.
For cardiovascular and prothrombotic risk factors, she
had a 25 years history of cigarette smoking (30–35 ciga-
rettes/day), a history of 16 months of postmenopausal
hormone replacement therapy (HRT) by oral intake of an
estrogen-gestagen combination (Presomen, 0.6 mg/d for
16 months) and untreated hypercholesterolemia (5.90
mmol/L, reference: <5.2 mmol/L). She had no previous
medical history of arrhythmia, ischemic heart disease, dia-
betes mellitus, or stroke. Duplex sonographic examina-
tion of the arterial system of the limbs revealed the acute
thromboembolic occlusion of the left popliteal artery.
Diagnostic work up was initiated to determine the source
of the embolism. The resting ECG and a holter monitor-
ing for 24 h disclosed normal sinus rhythm without any
pathologic findings. The transthoracic echocardiographic
examination (TTE) showed no structural or functional
cardiac abnormalities. Subsequently, a TEE was per-
formed for evaluation of the cardiac cavities and of the
thoracic aorta, revealing a large, pedunculated and hyper-
mobile thrombus (Figure 1, Panl A and B) attached to a
non-atherosclerotic aortic wall caudal of the left subcla-
vian artery. CT scans of the thoraco-abdominal aorta (Fig-
ure 2) confirmed the presence of the thrombus seen in
TEE. The entire thoracic aorta had normal dimensions
with no visible signs of atherosclerosis. For biochemical
laboratory parameters, thrombocytes (530*109/L, refer-
ence: <410*109/L), fibrinogen (5.5 g/L, normal: <3.50 g/
L) and total Cholesterol (5.90 mmol/L, reference: <5.2
mmol/L) were elevated. All other parameters including
glucose (5.8 mmol/L) and homocysteine (8.6 µmol/L)
levels were within the reference limit. An extensive sero-
logic survey for hypercoagulability, including antiphos-
pholipid antibodies, and vasculitis disorders was
negative.
Because of the high risk for recurrent peripheral emboliza-
tion due to the size and the hypermobility of the throm-
bus, the patient was admitted to the vascular surgery unit,
where a 15 cm long thrombus in the thoracic aorta with
its origin 5 cm distal of the left subclavian artery could be
removed. During surgery no macroscopical signs of inti-
mal lesions of the aorta could be detected. Histological
evaluation of the thrombus revealed a red, parietal throm-
bus without any evidence of malignancy. The postopera-
tive course was uneventfull and the patient was
discharged 10 days after the surgical intervention. The
patient was treated with vitamin-k-antagonist phenpro-
coumon (INR: 2.5–3.5) for secondary prevention of
thromboembolism and with 10 mg/d of atorvastatin for
hypercholesterolemia additional to cessation of smoking
and oral intake of HRT. On this therapeutic regimen, the
patient was asymptomatic with no pathologic findings in
the imaging workup at six months follow up.
Discussion
In this case report we demonstrate the presence of a large,
mobile thrombus in a morphologically normal aorta as
the source of PAE. While thrombi in aneurysmatic or
atherosclerotic aorta, especially in combination with pro-
thrombotic risk factors such as hypercoagulability,
antiphospholipid syndrome, disorders of protein C and S
and vasculitis, have previously been described, the pres-
ence of thrombi in a non-atherosclerotic aorta is a rare
Transesophageal echocardiographic cross-sectional (Panl A)  and longitudinal (Panel B) images of the descending thoracic  aorta showing the highly mobile, floating thrombus Figure 1
Transesophageal echocardiographic cross-sectional (Panl A) 
and longitudinal (Panel B) images of the descending thoracic 
aorta showing the highly mobile, floating thrombus. The orig-
inal lumen of the aorta (21 mm) is reduced by the thrombus 
to a circumferential patent lumen of 4–6 mm.Thrombosis Journal 2005, 3:19 http://www.thrombosisjournal.com/content/3/1/19
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event. As the aorta of the patient described in this case
report had normal dimensions and was free of any visible
atherosclerotic intimal lesions, the additive prothrom-
botic effects of hypercoagulability, due to increased level
of fibrinogen, thrombocytes and cholesterol, and of oral
HRT and excessive smoking seem most likely to be the
cause of the thrombus formation.
Plasma fibrinogen is an important component of the
coagulation cascade, as well as a major determinant of
blood viscosity and blood flow. Increasing evidence from
epidemiological studies suggests that elevated plasma
fibrinogen levels are associated with an increased risk of
cardiovascular disorders, including ischemic heart dis-
ease, stroke and thromboembolism [4]. The increase in
plasma fibrinogen levels may promote a prothrombotic
or hypercoagulable state, and may in part explain the risk
of stroke and thromboembolism. The independent and
close relation between fibrinogen and cardiovascular risk
including thromboembolic complications in the periph-
eral arterial system has been documented in a substantial
number of studies. Fibrinogen strongly affects blood coag-
ulation, blood rheology and platelet aggregation. In addi-
tion, it has direct effects on the vascular wall and is a
prominent acute phase reactant [5,6].
The adverse cardiovascular effects of HRT have been well
documented in the Women's Health Initiative (WHI) trial
[7-11]. The combined estrogens-progestin arm of the WHI
trial [8] demonstrated that some risks, such as for throm-
boembolism, coronary heart disease, and stroke, arise
within the first 1 to 2 years of therapy, while other risks
such as the risk for breast cancer appear to increase with
longer-term hormone therapy. In our patient, the throm-
boembolic event occurred 16 months after the initiation
of the HRT, which is consistent with the observation in
the WHI study. The recently published clinical recom-
mendations and guidelines[12] by the US Preventive Serv-
ices Task Force (USPSTF) on hormone therapy for the
prevention of chronic conditions in postmenopausal
women consider the harmful effects of combined estro-
gens and progestin likely to exceed the benefits of chronic
disease prevention. Therefore, it is recommended that the
decision of HRT for postmenopausal complaints should
be based on weighing the possible harm arising from the
individual risk factors and the benefit.
The combination of smoking and HRT is a substantial risk
factor for cardiovascular complications and a burden for
the public health care, regrading the fact that products for
HRT in the postmenopause are the second most fre-
quently prescribed drugs in the USA [13,14] and 50 % of
women on HRT are smokers [8]. Smoking per se not only
increaes the incidence of thrombotic events, it has also
been shown to decrease the level of serum estrogens by 50
% [15], thereby reducing, or even completely abolishing,
the well-established beneficial effects of estrogen such as
reducing hot flushes, prevention of osteoporosis and the
positive effect on lipid metabolism [13,14]. Cigarette
smoking induces global changes in both peripheral and
central vascular function [16]. Some authors postulate
that the most important effects of cigarette smoking in
promoting atherosclerosis and thromboembolic compli-
cations may be endothelial disturbance and fibrin forma-
tion [17]. Consequently, cessation of smoking is a crucial
preventive step towards minimizing the thromboembolic
risks.
Generally, thromboembolic events are associated with
advanced age, complex and ulcerated atherosclerotic
plaques to which the thrombus is attached. Interestingly,
the region around the left subclavian artery seem to be
one of the predisposed localization for thrombus forma-
tion [18]. However, as this case report in accordance with
few previously published studies demonstrate, it can also
affect younger patients. In the study by Laperche et al. [18]
the mean age of the 23 patients with aortic thrombus was
45 ± 8.4 years, with the youngest patient being 34 years
old. In their study, smoking was the leading risk factor (n
= 16) followed by hypercholesterolemia (n = 11) and ele-
vated fibrinogen levels (n = 10). In our patient all 3 risk
factors were present. In the study by Laperche et al. [18]
histopathological examination revealed microscopic fea-
Thoraco-abdominal CT-scan image showing the thrombus in  the thoracic aorta (arrow) Figure 2
Thoraco-abdominal CT-scan image showing the thrombus in 
the thoracic aorta (arrow).Thrombosis Journal 2005, 3:19 http://www.thrombosisjournal.com/content/3/1/19
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tures of atherosclerosis limited to the insertion site in all
patients undergoing surgery for thrombectomy. Consider-
ing the high thrombogenic potential of atherosclerotic
plaques [19], it is likely that the thrombus in our patient
was attached to an atherosclerotic plaque, even when it
was not visible on TEE. Perler et al. [20] reported previ-
ously about thromboembolic events originating from a
morphologically normal aorta in two young women. Both
patients were taking oral steroidal medications, and both
patients were heavy cigarette smokers. These cases and a
review of the previous literature suggest that the develop-
ment of aortic mural thrombi, at least in some patients,
may not always result from diffuse and advanced athero-
mas, but may constitute a separate and distinct clinical
entity of a premature atherosclerosis.
Detection of mobile thrombus of the thoracic aorta has
become increasingly common thanks to routine explora-
tion using TEE after any embolic events. TEE has been
shown to detect reliably aortic thrombi [21]. Using high-
frequency, multiplane probes, TEE sufficiently allows not
only the detection, it also provides such important infor-
mation as the size, the location and the implantation base
of the thrombus. It has previously been demonstrated that
these information obtained from TEE correlate well with
information obtained from macroscopic examination
[18]. The high spatial resolution allows detailed examina-
tion of the entire thoracic aorta as well as the intimal sur-
faces. Additionally, the real-time imaging provides
information such as the mobility of the thrombus, which
is not possible with CT. Such additional information,
however, is helpful for immediate and long-term thera-
peutic decision making. However, it must be emphasized
that the resolution capability of TEE is not sufficient to
detect accurately atherosclerotic changes in the aortic wall
at the microscopic level, as is possible with intravascular
ultrasound.
The abdominal aorta also constitutes a frequent origin for
thromboembolism [1,22]. This region, however, is not
accessible to TEE. Therefore, optimal approach for a com-
plete diagnostic workup for search of the thromboem-
bolic sources requires the synergistic use of at least two
modalities, i.e. TEE (for exploration of the cardiac and
thoracic aorta origins) and CT or MRI (for exploration of
the abdominal origins). The ubiquitaer availability, the
excellent sensitivity and specificity and immediate results
make TEE as the preferred and primarily used imaging
modality for diagnostic evaluation in such cases.
Several treatments have been used in different forms with
variable success for management of aortic thrombus,
including anticoagulant therapy alone [18,23], thrombol-
ysis [24], thromboaspiration and surgery [25]. At our
institution, we initiate immediate anticoagulant therapy
with heparin for 2 weeks after the thrombus is specified.
At the end of 2 weeks TEE (alternatively MRI) is per-
formed. If the thrombus shows reduction in size, the
heparin therapy is continued until the thrombus resolves.
If anticoagulant therapy fails, surgical intervention is con-
sidered. Surgical intervention is preferred to anticoagulant
regimen in young patients, in the presence of a large
hypermobile thrombus (as in this case report) and in
patients with recurrent embolic events. Similar therapeu-
tic strategies have also been suggested by others
[18,25,26]. Endovascular stent-grafting provides a new
minimally invasive therapeutic option in the treatment of
symptomatic mobile thoracic aortic thrombus [27], how-
ever, its role in the setting of aortic thrombosis regarding
the long term outcome is not established yet.
Evidence-based recommendations and guidelines regard-
ing the therapeutic management and the long-term sur-
veillance are lacking. Prospective studies are required to
address the issue of evidence based guidelines and opti-
mal approaches for the diagnostic, therapeutic and follow
up management of these patients.
Conclusion
Embolic events arising from thrombi within a non-aneu-
rysmatic, non-atherosclerotic aorta is a rare but possible
emergency event. Physicians have to be aware of the
higher risk for developing thromboembolic complication
in women under HRT in presence of additional prothrom-
botic risk factors such as smoking and hypercoagulability,
not only in the venous but also in the arterial vascular sys-
tem; therefore, profiling the individual risk and weighing
the benefits against the potential risks is warranted before
prescribing HRT. Transesophageal echocardiography
serves as the most appropriate initial imaging modality
for diagnostic work up and therapeutic management in
patients with peripheral embolic events.
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